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Abstract
Background: The present study was designed to examine the effect of chronic treatment with rosiglitazone -
thiazolidinedione used in the treatment of type 2 diabetes mellitus for its insulin sensitizing effects - on the Leydig
cell steroidogenic capacity and expression of the steroidogenic acute regulatory protein (StAR) and cholesterol
side-chain cleavage enzyme (P450scc) in normal adult rats.
Methods: Twelve adult male Wistar rats were treated with rosiglitazone (5 mg/kg) administered by gavage for 15
days. Twelve control animals were treated with the vehicle. The ability of rosiglitazone to directly affect the
production of testosterone by Leydig cells ex vivo was evaluated using isolated Leydig cells from rosiglitazone-
treated rats. Testosterone production was induced either by activators of the cAMP/PKA pathway (hCG and
dbcAMP) or substrates of steroidogenesis [22(R)-hydroxy-cholesterol (22(R)-OH-C), which is a substrate for the
P450scc enzyme, and pregnenolone, which is the product of the P450scc-catalyzed step]. Testosterone in plasma
and in incubation medium was measured by radioimmunoassay. The StAR and P450scc expression was detected
by immunocytochemistry.
Results: The levels of total circulating testosterone were not altered by rosiglitazone treatment. A decrease in basal
or induced testosterone production occurred in the Leydig cells of rosiglitazone-treated rats. The ultrastructural and
immunocytochemical analysis of Leydig cells from rosiglitazone-treated rats revealed cells with characteristics of
increased activity as well as increased StAR and P450scc expression, which are key proteins in androgen
biosynthesis. However, a number of rosiglitazone-treated cells exhibited significant mitochondrial damage.
Conclusion: The results revealed that the Leydig cells from rosiglitazone-treated rats showed significant reduction
in testosterone production under basal, hCG/dbcAMP- or 22 (R)-OH-C/pregnenolone-induced conditions, although
increased labeling of StAR and P450scc was detected in these cells by immunocytochemistry. The ultrastructural
study suggested that the lower levels of testosterone produced by these cells could be due to mitochondrial
damage induced by rosiglitazone.
Background
Rosiglitazone is a PPARg synthetic activator from the
group of thiazolidinediones (TZDs) often used in the
treatment of chronic diseases such as type 2 diabetes
and other forms of insulin resistance, as seen in polycys-
tic ovary syndrome (PCOS). Activation of PPARg by
TZDs improves insulin sensitivity and, consequently,
bodily glycemia and lipid control and reduces the con-
centration of plasma androgen in patients with PCOS
[1-5]. Besides their well-known effects on insulin sensi-
tivity and energy metabolism, TZDs have also been
reported to modulate steroid production in gonad tis-
sues. For example, TZDs stimulate progesterone secre-
tion in MA-10 Leydig tumor cells [6,7] and ovarian cells
[8]. Opposing effects of TZDs on androgen levels and/
or production in male humans [9-11] and animal mod-
els have been described [7,12-20]. An inhibitory effect of
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demonstrated in healthy men [11], while in obese male
Zucker rats [19] plasma testosterone was not affected by
this TZD. TZDs have also been reported to directly
inhibit steroidogenic enzymes and steroid secretion in
vitro, as evidenced by a decrease in the activity of 17a-
hydroxylase, 17,20-lyase, aromatase and 3b-hydroxyster-
oid dehydrogenase [7,12-18]. Although there is evidence
of the modulation of testosterone action and/or produc-
tion by TZDs, the effects of oral rosiglitazone treatment
on circulating plasma testosterone and/or production
have not been reported in experimental animal models.
The aim of the present study was to determine
whether oral rosiglitazone treatment influences testicular
production of testosterone using an ex-vivo model of
Leydig cells isolated from rosiglitazone-treated adult
male rats. Ultrastructural and immunocytochemical ana-
lysis of Leydig cell was performed to assess the cellular
integrity and the expression of StAR and P450scc, which
are key proteins in androgen biosynthesis.
Methods
Animals and experimental procedures
Twelve male Wistar-Albino rats (aged 8-9 weeks and
weighing 200-250 g) were used and obtained from the
Bioterium of the Department of Antibiotics, Universi-
dade Federal de Pernambuco, Brazil. The rats were kept
in a small colony in the animal house at a temperature
of 22 ± 3°C, with a 12:12 hour light/dark cycle, receiving
standard feed (Purina®) and water as required. The
experimental procedure was approved by the local
Ethics Committee for Animal Experimentation. The rats
were randomly divided into two groups of six animals
each. The test group received rosiglitazon (GlaxoS-
mithKline, Aranda de Duero, Spain) prepared using 1%
(v/v) Tween-80 (Sigma Chemical Co., St. Louis, MO,
USA) and administered daily via oral gavage at 5 mg/
kg/d. The control group received 1% vehicle. Both
groups were treated for 15 consecutive days. After treat-
ment, the rats were sacrificed with carbon dioxide. Fol-
lowing decapitation, truncal blood was collected in
heparinized tubes and kept on ice until the plasma was
obtained by centrifugation (600 × g, 15 min. 6°C). The
plasma was aliquoted and stored at -20°C until analysis
for testosterone concentration. The testes and seminal
vesicles were removed and weighed. The testes were
used for ex vivo assays and morphological analysis. The
dry weight of the seminal vesicles was determined by
drying these tissues in an oven overnight at 110°C.
Ex vivo study
For the ex vivo study, the testes from rosiglitazone-treated
or control rats were decapsulated and the Leydig cells
were isolated and purified as described in Wanderley and
Negro-Vilar [21], with slight modifications. Briefly, the
decapsulated testes were incubated in an enzyme solution
of 0.5 mg/ml collagenase (Sigma), 0.2 mg/ml soybean tryp-
sin inhibitor (Sigma) and 5 μg/ml leupeptin (Sigma) in
PBS (136.9 mM NaCl, 2.68 mM KCl, 8.1 mM Na2H-
PO4.7H2O, 1.47 mM KH2PO4) containing 0.1% bovine
serum albumin (PBS/BSA) (BSA, fraction V, ICN Biome-
dical, California, CA, USA), pH 7.4, in a shaking water
bath (20 min, 90 Hz, 34°C). The dispersed testes were sus-
pended in 50 ml (final volume) PBS/BSA and the disso-
ciated tubules were allowed to settle (5 min). The
supernatant was filtered and washed with 5 ml PBS/BSA.
The filtered cell suspension was centrifuged (150 × g, 15
min, 20°C). The pellet was re-suspended in 5 ml PBS/BSA,
loaded onto the top of a discontinuous Percoll (HE
Healthcare Bio-Sciences AB, Uppsala, Sweden) density
gradient (20%, 35%, 43%, 68% and 90%) and centrifuged at
800 × g for 30 min at 20°C. Cells in the 43-68% interface
(specific gravity: 1.0640-1.0960 g/ml) were collected,
washed twice with medium 199 (M199) (Gibco, Grand
Island, NY, USA) containing 0.1% BSA, re-suspended in
M199/0.1% BSA and used immediately for the experi-
ments. Cells (0.3 × 10
6 cells/0.5 ml) were treated (incu-
bated) for 2 h with M199 (basal testosterone), hCG
(Sigma) (1 mIU/ml), dbcAMP (Sigma) (1 mM), 22-hydro-
xycholesterol (Sigma) (10 μM) or pregnenolone (Sigma) (1
μM) (stimulated/induced testosterone) in a shaking water
bath (60 Hz, 34°C) in an atmosphere of 95% O2 and 5%
CO2. At the end of incubation, the cells were centrifuged.
The supernatant was collected and stored at -20°C until
testosterone measurement by radioimmunoassay (RIA).
To assess the effects of chronic treatment with rosiglita-
zone on cell viability the trypan blue exclusion was used.
The trypan blue exclusion is widely used screening
method to measure plasma membrane integrity. The try-
pan blue assay was performed after the period of 2 h incu-
bation of cells. Cells were incubated with trypan blue
(0,5%) for 20 min and the percentage of blue cells, indicat-
ing a capture of the colorant due to plasma membrane
rupture, were counted. 90-95% of no colored cells was
considered normal cell viability.
Light microscopy
The testes were fixed in Bouin’s solution for eight hours,
then dehydrated in an alcohol series and embedded in
paraffin wax. Serial sections of 4 μmw e r ec u tw i t ha
microtome (Leica RM 3125RT) and stained with hema-
toxylin-eosin for histological analysis [22].
Electron transmission microscopy
For routines procedures, the fragments of testes were
fixed overnight in a solution containing 2.5% glutaralde-
hyde (Sigma) and 4% paraformaldehyde (Sigma) in 0.1
M cacodylate (Sigma) buffer. After fixation, the samples
were washed twice in the same buffer and post-fixed in
a solution containing 1% osmium tetroxide (Sigma), 2
mM calcium chloride and 0.8% potassium ferricyanide
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and embedded in SPIN-PON resin (Embed 812). Poly-
merization was performed at 60°C for three days [23].
Ultrathin sections were collected on 300-mesh nickel
grids, counterstained with 5% uranyl acetate and lead
citrate and examined with a FEI Morgani 268D trans-
mission electron microscope. For the immunocytochem-
ical study, the isolated and hCG-stimulated Leydig cells
were fixed overnight in a solution containing 0.5% glu-
taraldehyde and 4% paraformaldehyde in 0.1 M phos-
phate buffer. After fixation, the samples were washed
three times in the same buffer, incubated with 50 mM
ammonium chloride for 40 min, dehydrated in alcohol
and embedded in LR-White resin (Electron Microscopy
Science, Washington, PA, USA). Polymerization was
performed at 30°C for five days. This procedure was car-
ried out as described by Peixoto et al. [24].
Immunocytochemistry
Ultrathin sections of isolated and hCG-stimulated Leydig
cells were cut with a diamond knife, collected on nickel
grids and incubated for 30 min. at room temperature in
0.02 M PBS, pH 7.2, containing 1% BSA and 0.1% Tween
20 (PBS-BT). The sections were then incubated for one
hour with primary antibodies against StAR and P450scc at
dilutions of 1:25 and 1:200, respectively, in PBS-BT. The
sections were then washed in PBS-BT and incubated with
a secondary antibody, 10 nm colloidal gold-labeled goat
anti-rabbit IgG. As an antibody control, sections were
incubated only in the presence of the gold-labeled marker.
Following the immunostaining procedures, the sections
were counterstained with 5% uranyl acetate and lead
citrate [24]. Quantitative analysis was performed on
photomicrographs at a final magnification of 28’000× of
10 different Leydig cells, showing the entire profile and
randomly chosen, in order to compare the number of
gold-labeled particles in the control and rosiglitazone-trea-
ted cells using the Student’s t test. Since the experimen-
tally treated cells and control samples were processed in
an identical method, no correction for tissue shrinkage
was performed.
Antibodies
The polyclonal antibodies StAR (sc-25806, Santa Cruz
Biotechnology, INC., Santa Cruz, CA, USA) and cyto-
chrome P450scc enzyme (AB1244, Chemicon Interna-
tional, Inc., Canada) were raised in rabbits against
different peptides corresponding to amino acids 1-285
representing full-length StAR of human origin and
amino acids 421-441 of the rat cytochrome P450scc
enzyme, respectively. The 10-nm colloidal gold-labeled
goat anti-rabbit IgG was purchased from Sigma Chemi-
cal Co. (St. Louis, MO, USA).
Radioimmunoassay and statistical analysis
Testosterone was measured in plasma (with extraction)
and directly (without extraction) in the incubation
medium by a charcoal-dextran RIA [25] that employs
[
3H]-testosterone as a tracer and primary antiserum
raised in rabbits in our laboratory against testosterone-
3-(0-carboxymethyl)oxime:BSA. Intra-assay and inter-
assay coefficients of variation were 8.1% and 15.1%,
respectively. The testosterone antibody demonstrated <
0.1% cross-reactivity with androstenedione, dehydroe-
piandrosterone, androsterone, 17a-hydroxyprogesterone,
b-estradiol and estrone. None of the substances tested
interfered with the assays. The data from the different
analyses are expressed as the mean ± SEM of six repli-
cates determinations for plasma and triplicate determi-
nations for incubation medium and were representative
of results obtained in at least two similar experiments.
The Student’s t test, one-way analysis of variance
(ANOVA) and Dunnett’s test were used to determine
differences between control and rosiglitazone-treated
plasma and cells, respectively. P-values less than 0.05
were considered statistically significant.
Results
Body weight, testis weight, seminal vesicle weight and
plasma testosterone
The treatment of rats with rosiglitazone did not induce
changes in body weight or the relative weight of the
testes or dried seminal vesicles (data not shown). Total
plasma testosterone was not significantly modified by
the treatment with rosiglitazone (control: 25.01 ± 3.5;
rosiglitazone: 38.4 ± 7.0 ng/ml), which may explain the
unaltered weight of the seminal vesicles, since it is
known that testosterone supports the trophism of this
organ.
Ex vivo testosterone secretion
These experiments examined the impact of chronic
treatment with rosiglitazone on the steroidogenic
response of Leydig cells to direct induction by activators
of the cAMP/PKA pathway (hCG and dbcAMP), which
is the major signaling pathway regulating steroidogenesis
[26], and by substrates of steroidogenesis (22-OH-C and
pregnenolone). The objective of the use of these sub-
strates was to determine whether the limiting-steps of
steroidogenesis - the transportation of cholesterol from
outer to inner mitochondrial membrane by the StAR
protein and the cleavage of the cholesterol side chain by
mitochondrial P450scc to yield pregnenolone - were
affected by rosiglitazone treatment. Rosiglitazone treat-
ment modified the steroidogenic response, resulting in a
decrease in testosterone production under basal, hCG/
dbcAMP- or 22 (R)-OH-C/pregnenolone-induced condi-
tions (Figure 1). This reduced steroidogenic response to
stimulators/inducers of testosterone production can be
seen by the reduction in the magnitude of the stimula-
tion/induction obtained in both the control and rosigli-
tazone-treated groups. The increase in testosterone
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control rats was 24.1-fold (± 1.2) and 22.9-fold (± 5.5),
respectively, whereas the increase in production in cells
from rosiglitazone-treated rats was 12.4-fold (± 0.4) and
10.5-fold (± 0.2), respectively. Similarly, the increase in
testosterone production induced by 22(R)-OH-C and
pregnenolone in cells from control rats was 77.0-fold (±
33.0) and 34.4-fold (± 0.9), respectively, whereas the
increase in production in cells from rosiglitazone-treated
rats was 46.0-fold (± 39.3) and 35.4-fold (± 20.2),
respectively. These results indicate that the rosiglitazone
treatment decreases the function of multiple steroido-
genic enzymes, including P450scc. In order to evaluate
whether the inhibitory effect of the chronic treatment
with rosiglitazone on testosterone production was due
to a decrease in cell viability, the trypan blue exclusion
assay was used. This test demonstrated that inhibition
was not due to the toxicity of rosiglitazone per se, as the
percentages of integral cells obtained after 2 h of incu-
bation were comparable between the cells from rosiglita-
zone-treated (93%) and from controls (95%) rats.
Histological analysis
No morphological differences were found in Leydig cells
between the control and experimental groups (data not
shown).
Electron microscopy analysis
The morphological characteristics of control Leydig cells
were an irregular polygonal shape with an asymmetrical
nucleus located eccentrically in the cell body. The filo-
podia were protruded and interdigitated with the filopo-
dia from opposite cells. The tubular smooth
endoplasmic reticulum (SER) was abundant, consisting
of interconnected, branched and anastomosing tubules
throughout the cytoplasm. This tubular SER was occa-
sionally surrounding mitochondria and lipid droplets.
The rough endoplasmic reticulum (RER) was scarce,
located mainly in perinuclear and peripheral regions.
Mitochondria of variable size and with tubular and thick
cristae were numerous and scattered throughout the
cytoplasm. Several Golgi complexes were dispersed in
the cell body, often found near a cell pole, since the
nucleus is eccentrically located. Peroxisomes of irregular
sizes were identified in portions of the cytoplasm (Figure
2:A). Rosiglitazone-treated Leydig cells presented all the
organelles cited above. However, some differences were
observed, such as a vesicular SER, consisting of sepa-
rated vesicles of variable diameters and dilated Golgi
complexes, which are typical alterations of an activated
steroidogenic cell. However, several Leydig cells exhib-
ited enlarged, vacuolated mitochondria with disarranged
or discontinuous cristae (Figure 2:B and 2:C).
StAR and P450scc in Leydig cells
Immunocytochemistry revealed that the enzymatic ster-
oidogenic pathway was significantly more active in the
Leydig cells treated with rosiglitazone. More evident
StAR and P450scc labeling was detected throughout the
cytoplasm of treated cells in comparison to control sam-
ples (Figures 3 and 4).
Discussion
Thiazolidinediones (TZDs) are frequently administered
to patients with insulin resistance associated with type II
diabetes [for a review, see [27-29]]. Moreover, there is
growing evidence that the biological effects of TDZs go
Figure 1 Ex vivo production of testosterone in Leydig cells isolated from control or rosiglitazone-treated (RSG-treated) rats; Leydig
cells (0.3 × 10
6/0.5 ml) were incubated for 2 h with M199, hCG (1 mIU/ml), dbcAMP (1 mM), 22-OH-C (10 μM) or pregnenolone (1
μM). Results are the mean ± SEM of three determinations; *p < 0.001 (ANOVA).
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strated that TDZs have a considerable impact on the
production and metabolism of gonad hormones
[6,8,14,17-20]. Rosiglitazone and other thiazolidine-
diones are known to affect testosterone production in
humans [10,11,31]. However, effects of rosiglitazone on
testosterone level and synthesis have not been reported
in experimental animal models. Therefore, the present
study investigated the effect of chronic treatment with
rosiglitazone on plasma testosterone levels, steroidogenic
response and morphology of Leydig cells in normal rats.
Steroid hormones are synthesized from cholesterol in
the gonads in response to pituitary hormones, such as
LH/hCG via the classic cAMP/PKA pathway. The main
rate-limiting step in the steroidogenenic pathway is the
transportation of cholesterol from the outer to inner
mitochondrial membrane by a transmembrane protein,
StAR protein, the expression and activation of which is
maintained by cAMP modulated PKA under maximal
stimulation of LH [32].
In the present study, normal rats exposed to rosiglita-
zone underwent no changes in the level of total plasma
testosterone when compared with the controls. A num-
ber of authors have reported contrasting results regard-
ing the impact of TZDs on plasma testosterone levels in
different clinical and experimental models. In male
Zucker diabetic fatty (ZDP) rats, rosiglitazone treatment
did not alter plasma testosterone levels [19,33]. In
healthy men, rosiglitazone decreased testosterone and
dihydrotestosterone (DHT) production rates [11]. In
women with PCOS and hyperandrogenism, TZD treat-
ment increases sex hormone binding globulin (SHBG)
levels in plasma, leading to a decrease in free-circulating
testosterone levels [34]. Circulating testosterone is
known to be present in three major fractions: free, albu-
min-bound and sex hormone binding globulin (SHBG)
[ 3 5 ] .I nc o n t r a s tt ow o m e n ,m e nw i t ht y p e2d i a b e t e s
have low testosterone levels and treatment with rosigli-
tazone induces an increase in the three fractions of cir-
culating testosterone and SHBG levels [36]. As the
testosterone measured in the present study represents
the total circulating fraction, the measurement of the
other two fractions (free and albumin-bound) would be
necessary for a better assessment of the effect of rosigli-
tazone treatment in the present study. However, unlike
the human, adult rats do not express SHBG [37]. Addi-
tionally, the possibility of decreased clearance rate of
testosterone can not be excluded.
In the ex vivo experiments, basal testosterone pro-
duction was reduced by chronic treatment with rosigli-
tazone and Leydig cells from rosiglitazone-treated rats
were less responsive to cAMP/PKA pathway activation
of testosterone production than those from control
rats. The ex vivo model is based on the ability of hCG/
Figure 2 Testis Leydig Cells; A - Untreated Leydig cells with
nucleus, Golgi complex (arrows), SER, RER and mitochondria;
Bar 1 μm; B and C - Leydig cells treated with rosiglitazone
showing dilated and vacuolated mitochondria (star), vesicular
smooth endoplasmic reticulum and dilated Golgi complex
(arrows); Bars 1 μm and 0.5 μm, respectively; M, mitochondria;
N, nucleus; RER, rough endoplasmic reticulum; SER, smooth
endoplasmic reticulum.
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dig cells in vitro through a mechanism involving PKA
activation [26]. The results of the present study suggest
a direct effect of rosiglitazone on basal and stimulated
testosterone secretion on the PKA level and/or at a
p o i n td o w n s t r e a mf r o mP K Aactivation. To further
study the earlier steps (before and after mitochondrial
P450scc-catalyzed conversion of cholesterol into preg-
nenolone) of the steroidogenic pathway, 22 (R)-OH-C-
induced and pregnenolone-induced testosterone pro-
duction was also examined. 22 (R)-OH-C replaces cho-
lesterol because it is membrane-permeable. The high
concentrations used were to obviate the interference of
any endogenous precursor. When Leydig cells from
rosiglitazone-treated rats were challenged with 22 (R)-
OH-C or pregnenolone, a reduction in testosterone
production occurred, indicating that substrate
(cholesterol) availability was not affected by the treat-
ment with rosiglitazone, but rather multiple steroido-
genic enzymes were limiting.
Morphological analysis of the testis was performed to
determine whether the reduced testosterone production
in the testes of rosiglitazone-treated rats was due to
structural alterations in this tissue or a reduced amount
of the proteins involved in the limiting steps of steroi-
dogenesis - StAR and P450scc. Rosiglitazone-treated
rats had Leydig cells with activated morphological char-
acteristics, such as vesicular SER, dilated Golgi com-
plexes and few or no lipid droplets. According to Ohata
[38], after stimulation with gonadotropin, the inactive
tubular SER is converted into vesicles of variable sizes
and the author found either hypertrophy or dilatation of
the Golgi complexes, which are both related to
enhanced secretory cell function. Moreover, activated
Figure 3 StAR and P450scc immunocytochemistry; A and C - little labeling was observed in control samples for StAR (A) and P450scc
(C) (arrows); B and D - increased labeling of StAR (B) and P450scc (D) was detected in rosiglitazone-treated Leydig cell (arrows); L,
Lipid droplets; M, mitocondria; N, nucleus; SER, smooth endoplasmic reticulum; Bars 500 nm.
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droplets, since the cholesterol contained in the droplets
is consumed for the synthesis of steroid. In the present
study, rosiglitazone-treated Leydig cells exhibited some
vacuolated, enlarged mitochondria distributed through-
out cytoplasm. This altered mitochondrial morphology
could lead to mitochondrial dysfunction. It has been
demonstrated in rat and human hepatocytes, that thia-
zolidinediones cause mitochondrial dysfunction, fol-
lowed by increased permeability, calcium influx, and
nuclear condensation [39]. The order of toxicity by
which thiazolidinediones cause mitochondrial dysfunc-
tion is troglitazone pioglitazone and rosiglitazone
[40,41]. Although experimental studies on hepatocytes
and isolated mitochondria have indicated that troglita-
zone but not rosiglitazone or pioglitazone induces mito-
chondrial dysfunction [39,40], it is possible that the
chronic exposure to rosiglitazone, as used in the present
study, could lead to mitochondrial damage. It has been
proposed by Feinstein et al. (2005) that this effect of
thiazolidinediones are PPARg-independent and results
from a direct interaction of the drugs with mitochon-
dria, altering bioenergetics and potentially increasing
reactive oxygen species production and causing ATP
depletion. Recently, the importance of intact mitochon-
dria with active respiration for LH-mediated Leydig cell
steroidogenesis has been showed [41,42]. These authors
showed that maintenance of mitochondrial membrane
potencial, mitochondrial ATP synthesis, and mitochon-
drial pH are all required for acute steroid biosynthesis.
The observed alteration in the state of mitochondria
induced by rosiglitazone in our experiments could
explain the lower levels of testosterone produced by
these cells.
Protein expression levels were evaluated through
immunocytochemistry. Leydig cells from rosiglitazone-
treated animals exhibited more expressive immunola-
belling for StAR and P450scc when compared to con-
trol samples. These results are apparently
contradictory to the reduced testosterone production
by Leydig cells found in the ex vivo experiments. How-
ever, studying human ovarian cells in cultures, Seto-
Y o u n ge ta l .[ 4 3 ]f o u n dt h a tr o s i g l i t a z o n ea n dp i o g l i t a -
zone stimulated the expression of PPARg,i n s u l i n
receptor, IRS-1 and StAR, in contrast to results
obtained by the authors in a previous report [44], in
which thiazolidinediones stimulated progesterone pro-
duction, but inhibited estradiol and testosterone pro-
duction in ovarian cells. Recently, other authors found
that rosiglitazone stimulated StAR expression but did
not affect estradiol and progesterone production by
human ovarian cells [45]. The morphological analysis
of rosiglitazone-treated testes in the present study
revealed important structural damage in the mitochon-
dria of Leydig cells. This alteration could affect
(reduce) the function of the StAR and the steroido-
genic enzyme P450scc located in the mitochondria,
even at high levels of expression of both proteins. It is
also possible that other enzymes of the steroidogenic
process are affected by rosiglitazone. Previous in vitro
studies have demonstrated that thiazolidinediones inhi-
bit the activity of 17a-hydroxylase/17,20-lyase
[7,12,14,15], which are key enzymes in human andro-
gen synthesis, and aromatase [13].
Figure 4 Quantitative analysis of gold-labeled particle distribution in control and rosiglitazone-treated (RSG) Leydig cells; Significant
changes were found in treated cells (*Student’s t test, p < 0.0002). Mean of gold-labeled particles (mean ± S.D); N = 10.
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expression of PPARg has been demonstrated in Leydig
cells and an increase in PPARg mRNA and protein
levels has been observed in these cells after chronic
treatment with glitazones [33,46]. Therefore, it seems
reasonable that the expression of StAR and P450scc
observed in the present study may be mediated by the
nuclear receptor PPARg. However, the mitochondrial
damage could indicate that the influence of rosiglitazone
on testosterone production could also be PPARg-
independent.
Conclusion
In summary, the present study was designed to examine
the effect of chronic treatment with rosiglitazone on the
steroidogenic capacity of Leydig cells in normal adult
rats. The results revealed that the Leydig cells from rosi-
glitazone-treated rats showed significant reduction in
testosterone production under basal, hCG/dbcAMP- or
22 (R)-OH-C/pregnenolone-induced conditions,
although increased labeling of StAR and P450scc was
detected in these cells by immunocytochemistry. The
ultrastructural study suggested that the lower levels of
testosterone produced by these cells could be due to
mitochondrial damage induced by rosiglitazone. Further
studies are necessary to evaluate the impact of chronic
treatment with rosiglitazone on the activity of the StAR
and steroidogenic enzymes involved in testosterone pro-
duction. Although the present study does not permit
distinguishing a pituitary gland from the direct effect of
rosiglitazone, the observation that this TDZ reduces tes-
tosterone production in an ex vivo model indicates that
rosiglitazone has direct effects on Leydig cells that are
independent of the effects of the drug on the secretion
of gonadotropin. Finally, rosiglitazone action in testicu-
lar steroidogenesis is potentially of physiological and
pathophysiological significance.
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